Healthcare

Telix Pharmaceuticals Limited (NASDAQ: TLX) reported 1H revenue of $477 million as adjusted EBITDA surged 146% to $52 million, driven by robust product sales and a $40 million collaboration milestone from Regeneron.

Arbutus Biopharma Corporation (NASDAQ: ABUS) shares closed up 9% at $5.21 after the company announced a modified Dutch auction tender offer to buy back as much as $230 million in common stock at a price range of $5.00 to $5.75 per share.

Senti Biosciences, Inc. (NASDAQ: SNTI) subsidiary Senti Holdings finalized a $4 million senior secured convertible note issuance to Celadon Partners SPV 24, securing immediate funding.

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced a modified Dutch auction tender offer to buy back as much as $230 million in common stock at a price range of $5.00 to $5.75 per share.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares closed down 8% at $8.29 after UBS adjusted its price target to $7 from $4, while reaffirming a Neutral rating.

Gossamer Bio, Inc. (NASDAQ: GOSS) finalized a private placement financing agreement for as much as $250 million linked to seralutinib development, featuring a $25 million upfront payment and $125 million contingent on FDA acceptance of the PAH NDA.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) shares closed up 21% at $6.28 after the company priced a $2.0 million registered direct offering of 307,692 shares, adding modest near-term capital.